Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Thrombosis Stories

2013-09-04 12:33:48

BOSTON, Sept. 4, 2013 /PRNewswire/ -- The North American Thrombosis Forum (NATF), a non-profit organization working to increase public awareness of thrombosis and related cardiovascular diseases, has selected Marc Pfeffer, MD, PhD, as the recipient of the 2(nd) annual Arthur A. Sasahara, MD Lectureship Award. The Arthur A. Sasahara, MD Lectureship Award was introduced in 2012 to salute NATF Founding Board Member and longtime esteemed colleague, Dr. Art Sasahara, for his pioneering...

2013-09-03 23:27:05

A recently filed NuvaRing lawsuit alleges that the plaintiff developed pulmonary embolism, a potentially fatal condition, after and as a direct result of using NuvaRing. New York, NY (PRWEB) September 03, 2013 Alonso Krangle’s lawyers have filed a NuvaRing lawsuit due to a pulmonary embolism on behalf of a woman from Louisiana. This case (Case No. 2:13-cv-02933-SDW-MCA) was filed on May 13, 2013 in the U.S. District Court of New Jersey and specifically names the defendants to be...

2013-09-03 12:26:34

-- GARFIELD Registry presentations at ESC CONGRESS 2013 provide outcomes data on real-world treatment patterns of at-risk AF populations -- AMSTERDAM, Sept. 3, 2013 /PRNewswire/ -- One-year outcomes data from the first cohort of the Global Anticoagulant Registry in the FIELD (GARFIELD), an innovative, independent academic research initiative, provide insights into the elevated stroke risk among subpopulations of patients with atrial fibrillation (AF). The findings, from eight abstracts...

2013-09-03 12:26:04

-- Four-year GARFIELD VTE Registry to prospectively follow 10,000 patients worldwide who have venous blood clots and are candidates for anticoagulant therapy -- AMSTERDAM, Sept. 3, 2013 /PRNewswire/ -- The Thrombosis Research Institute (TRI) today announced the launch of the GARFIELD (Global Anticoagulant Registry in the FIELD) VTE Registry, an innovative research initiative exploring acute and long-term management and outcomes in patients with symptomatic venous thromboembolism...

2013-09-03 08:27:59

PRADAXA continues to drive Boehringer Ingelheim's commitment to innovation and research in cardiovascular diseases RIDGEFIELD, Conn., Sept. 3, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today confirmed research currently underway for Pradaxa® (dabigatran etexilate mesylate) in new cardiovascular patient populations, as well as robust plans to gather real-world evidence in patients with non-valvular atrial fibrillation (NVAF). These plans are the cornerstone of an...

2013-09-02 19:12:32

French analysis of more than 15,000 patients showed that women were undertreated with antithrombotic medications compared to men regardless of their stroke risk and comorbidities General practitioners (GPs) undertreat women with atrial fibrillation (AF), according to research presented at ESC Congress 2013 today by Dr Pierre Sabouret from France. The analysis of more than 15,000 patients showed that women were undertreated with antithrombotic medications compared to men regardless of their...

2013-09-02 09:58:04

Dr Benn Christiansen said: "We know that atrial fibrillation increases the risk of ischemic stroke. And in patients with atrial fibrillation or previous ischemic stroke, the risk of stroke increases with the number of risk factors. But until now, little attention has been paid to the association between stroke risk and risk factors in patients without prior stroke or atrial fibrillation. We wanted to explore that association and to quantify if stroke risk was of comparable size in patients...

2013-09-01 04:20:21

- Hokusai-VTE, the first global phase 3 double-blind study for once-daily edoxaban and the largest single comparative study for this patient population, achieves these results in a broad spectrum of VTE patients, including those with severe pulmonary embolism TOKYO, Sept. 1, 2013 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced results from the global phase 3 Hokusai-VTE study of 8,292 patients with either acute symptomatic deep vein...

2013-09-01 04:20:15

RIDGEFIELD, Conn., Sept. 1, 2013 /PRNewswire/ -- Today, data from the RE-ALIGN(TM) trial of dabigatran etexilate mesylate in patients with mechanical prosthetic heart valves were presented at the European Society of Cardiology (ESC) congress in Amsterdam, Netherlands, and published online in the New England Journal of Medicine. As part of Boehringer Ingelheim Pharmaceuticals, Inc.'s ongoing commitment to transparency, we previously announced on December 11, 2012, that this trial had been...

2013-08-29 12:25:33

The Markets for Both VTE Primary Prophylaxis and VTE Treatment/Secondary Prophylaxis Will Grow to $7.3 Billion in 2022, According to a New Report from Decision Resources BURLINGTON, Mass., Aug. 29, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that Bayer/Janssen's Xarelto will be the sales-leading therapy among the novel oral anticoagulants in the combined venous thromboembolism...